Author: Dr Olivia Charlton, Resident Medical Officer, St George Hospital, Sydney, NSW, Australia. DermNet NZ Editor in Chief: A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy editor: Gus Mitchell. October 2017.
Morbihan disease was first described in 1957 by French dermatologist Robert Degos, and is characterised by a firm oedema on the upper portion of the face. Although generally considered as a refractory and chronic form of rosacea, Morbihan disease may exist in the absence of other features of rosacea, and thus may represent a separate disease process.
Morbihan disease usually affects Caucasians in the third and fourth decade of life.
There are only two reports of the disease in skin of colour . It is more common in women than men.
The lymphoedema of Morbihan disease follows the loss of lymph vessel wall integrity and transudation of fluid. [3,4] The cause is unknown, but possible causes have been speculated, such as:
Morbihan disease is characterised by erythema and solid, non-pitting oedema.
Persistent facial oedema leads to:
There are no biochemical or histopathologic findings specific to Morbihan disease.
Biopsy should be conducted to rule out other diagnoses. Nonspecific histopathology findings include:
Differential diagnosis includes other granulomatous and inflammatory facial conditions [8,9].
Morbihan disease is frequently refractory to treatment.
Surgical excision of redundant edematous tissue may be required for a full recovery. Other options are:
Facial massage can be used to improve lymphatic drainage. Contact irritants or allergens should be avoided to aid recovery.
See the DermNet NZ bookstore.
© 2018 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.